OLGA and OLGIM Stage System for Gastric Cancer

Completed

• Conditions: Atrophic Gastritis; Stomach Neoplasms; Intestinal Metaplasia

• Registration Number: NCT03380052
• Lead Sponsor: Seoul National University Bundang Hospital

Brief Summary

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

Detailed Description

To validated the OLGA and OLGIM staging system with serum pepsinogen to estimate gastric cancer risk according to Lauren's histologic classification in South Korea, where the incidence rate of GC is high. In addition, the investigators attempted to investigate the interaction among the several risk factors including OLGA or OLGIM staging system for the risk of GC to help establish surveillance strategy.

Study Timeline

• Study Start: 2006-02
• Study First Submitted: 2017-12-16
• Study First Submitted QC: 2017-12-16
• Study First Posted: 2017-12-20
• Primary Completion: 2021-01
• Study Completion: 2022-01
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-12
• Last Update Posted: 2023-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2900

Inclusion Criteria

• Control group

  • those who were between 25 and 80 years old and did not have any evidence of gastric cancer and gastric dysplasia, esophageal tumor and MALToma in upper gastrointestinal endoscopy

• Gastric cancer group

  • Patients diagnosed as gastric cancer in the upper gastrointestinal endoscopy at the time of participating in the study between 25 and 80 years old.

Exclusion Criteria

• history of previous gastrointestinal surgery,
• any other malignancy
• cardia cancer
• who do not perform endoscopic biopsy
• pathologically proven gastric dysplasia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk	per 1 year	To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification

Trial Locations

Locations (1)

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of